News OptiNose, Inc.

Equities

OPTN

US68404V1008

Real-time Estimate Cboe BZX Other stock markets 13:47:30 2024-04-29 EDT			5-day change	1st Jan Change
0.862 ^USD	+0.19%		-17.72%	-34.30%

04-25	OptiNose, Inc. Provides Revenue Guidance for the First Quarter of 2024	CI
04-25	Transcript : OptiNose, Inc. - Special Call

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

OptiNose, Inc. Provides Revenue Guidance for the First Quarter of 2024	04-25	CI
Transcript : OptiNose, Inc. - Special Call	04-25
Optinose Provides Corporate Update on XHANCE Launch and Outlook and Announces Preliminary First Quarter 2024 XHANCE Net Revenue of $14.9 million	04-25	AQ
OptiNose, Inc. Provides Earnings Guidance for the Full Year 2025	04-25	CI
Optinose, Inc. Announces Preliminary XHANCE Net Product Revenue Results for the First Quarter Ended March 31, 2024	04-25	CI
Optinose to Present at the Needham Virtual Healthcare Conference	04-04	AQ
Lake Street Adjusts Price Target on OptiNose to $4 From $3, Maintains Buy Rating	03-18	MT
Sector Update: Health Care Stocks Steady Premarket Monday	03-18	MT
OptiNose Says US FDA Approves Xhance to Treat Chronic Rhinosinusitis	03-15	MT
Optinose Says FDA Approves Xhance to Treat Chronic Rhinosinusitis	03-15	DJ
XHANCE Approved by FDA as First and Only Medication Indicated for Treatment of Adults with Chronic Rhinosinusitis without Nasal Polyps	03-15	AQ
OptiNose, Inc. Announces U.S. Food and Drug Administration Approved XHANCE (Fluticasone Propionate) Nasal Spray for the Treatment of Chronic Rhinosinusitis Without Nasal Polyps in Patients 18 Years of Age and Older	03-15	CI
Optinose, Inc. Provides Update on Hikma Manufacturing Agreement	03-14	CI
Thinking about buying stock in CXApp, CCSC Technology International, Vroom, Spero Therapeutics, or OptiNose?	03-14	PR
HC Wainwright Initiates OptiNose With Buy Rating, $5 Price Target	03-11	MT
Transcript : OptiNose, Inc., Q4 2023 Earnings Call, Mar 07, 2024	03-07
OptiNose: Q4 Earnings Snapshot	03-07	AQ
Earnings Flash (OPTN) OPTINOSE Posts Q4 Revenue $19.9M	03-07	MT
OptiNose, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-07	CI
Optinose Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights	03-07	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News OptiNose, Inc.

Equities

OPTN

US68404V1008

Summary

Filters